Oncology Clinical Trials

$1,995.00

This data-driven report focuses exclusively on Phase 1, 2 and 3 benchmarks for 29 oncology clinical trials across more than 10 primary oncology indications. Purchase this report to benchmark oncology clinical trials with individual and average per-patient and per-patient-per-month costs for each development phase. Compare average planned and actual trial duration while seeing how timelines influence total costs — and see how outsourcing can help. Control budgets, set staffing levels and track key cost-drivers of oncology clinical trials.

Download a benchmarking report summarySpeak to a pharmaceutical benchmarking expert

Report Details

Publication Date: February 2013
Pages: 209
Chapters: 3
Metrics: 500+
Charts/Graphics: 140+

Top Reasons to Buy this Oncology Clinical Trials Report

Control budgets and accelerate timelines: Benchmark oncology trials of different sizes and durations with individual and average per patient and per patient per month costs for each development phase.  Compare average planned and actual trial durations while seeing how trial duration influences total costs — and see how outsourcing can help.

Manage critical cost-drivers: Track the shifting impact of key cost-drivers, such as patient enrollment and trial duration, as a product moves through development.  At the same time, see how an adequate number of sites encourages patient enrollment — a critical challenge for any trial.

Right-size your trial teams: Set optimal staffing levels for both CRAs and trial managers to handle trial sites and patients for each development phase — the report showcases average staffing for 12 key positions across all oncology phases.  Benchmark metrics such as number of sites per CRA and number of patients per CRA.

You may also be interested in CEIConnect: The Lifesciences Industry’s On-Demand Research Resource as well as our individual clinical development research reports.

Excerpt from Oncology Clinical Trials

The US National Cancer Institute estimated that 2012 saw 1.6 million newly diagnosed cancer cases and a total of 577,000 cancer deaths in the United States alone. According to the World Health Organization, 7.6 million people died from cancer in 2008. Incidence rates of prostate cancer in US men have risen to 1.4 for every 1,000. Furthermore, a commonly held theory asserts that one out of every nine women will develop breast cancer at some point in their lives. In one way or another, cancer affects everyone.

The pharmaceutical industry has taken clear steps to address the medical community’s unmet oncology needs. According to the data service BioPharm Insight, oncology research is the most active therapeutic area. Oncology boasts 10,303 active drug programs, accounting for 18% of all drug programs. illustrates the current status of the top 10 areas of cancer research. More common diseases such as breast cancer and prostate cancer have been studied extensively. In fact, great breakthroughs have been made, including 188 approved treatments for breast cancer and 99 for prostate cancer.

Table of Contents

11           Executive Summary

16           Study Methodology

17           Study Definitions

19           Oncology Clinical Trials: Key Findings

27           Phase 1 Oncology Trials

30           Phase 1 Cost-Drivers

37           Phase 1 Staffing

43           Phase 1 Oncology Trial Case Studies

46           Oncology Trial A

50           Oncology Trial B

54           Oncology Trial C

58           Oncology Trial D

62           Oncology Trial E

66           Oncology Trial F

69           Oncology Trial G

73           Oncology Trial H

77           Oncology Trial I

81           Oncology Trial J

85           Oncology Trial K

89           Phase 2 Oncology Trials

92           Phase 2 Cost-Drivers

99           Phase 2 Staffing

106        Phase 2 Oncology Trial Case Studies

109        Oncology Trial L

113        Oncology Trial M

118        Oncology Trial N

122        Oncology Trial O

127        Oncology Trial P

132        Oncology Trial Q

137        Oncology Trial R

142        Oncology Trial S

146        Oncology Trial T

150        Phase 3 Oncology Trials

153        Phase 3 Cost-Drivers

161         Phase 3 Staffing

168        Phase 3 Oncology Trial Case Studies

171        Oncology Trial U

176        Oncology Trial V

181        Oncology Trial W

186         Oncology Trial X

191        Oncology Trial Y

196        Oncology Trial Z

200        Oncology Trial AA

204        Oncology Trial BB

208        Oncology Trial CC

Charts and Graphics

11           Executive Summary

12           Figure E.1: Active Oncology Drug Programs, by Indication

19           Oncology Clinical Trials: Key Findings

20           Figure E.2: Range and Average Cost Per Patient, by Phase

21           Figure E.3: Range and Average Trial Duration, by Phase

24           Figure E.4: Range and Average Number of Patients Per Site, by Phase

25           Figure E.5: Range and Average Number of CRAs, by Phase

26           Figure E.6: Range and Average Number of Sites Per CRA, by Phase

27           Phase 1 Oncology Trials

28           Figure 1.1: Phase 1 Total Trial Costs, by Trial

29           Figure 1.2: Phase 1 Percentage of Costs Outsourced, by Trial

30           Figure 1.3: Phase 1 Average Planned and Actual Patient Enrollment

30           Phase 1 Cost-Drivers

31           Figure 1.4: Phase 1 Planned and Actual Patient Enrollment, by Trial

32           Figure 1.5: Patient Enrollment Drives Phase 1 Trial Costs

33           Figure 1.6: Phase 1 Cost Per Patient, by Trial

34           Figure 1.7: Phase 1 Actual Duration, by Trial

35           Figure 1.8: Trial Duration Drives Phase 1 Trial Costs

36           Figure 1.9: Phase 1 Cost Per Patient Per Month, by Trial

37           Phase 1 Staffing

38           Figure 1.10: Average Phase 1 Staffing, by Position

39           Figure 1.11: Phase 1 Number of Patients Per CRA, by Trial

40           Figure 1.12: Phase 1 Number of Sites, by Trial

41           Figure 1.13: Number of Patients Per Site, by Trial

42           Figure 1.14: Phase 1 Number of Sites Per CRA, by Trial

43           Phase 1 Oncology Trial CASE STUDIES

46           Oncology Trial A

47           Figure 1.15: Oncology Trial A: Background and Budget

48           Figure 1.16: Oncology Trial A: Cost Metrics and Staffing

49           Figure 1.17: Oncology Trial A: Duration and Enrollment

50           Oncology Trial B

51           Figure 1.18: Oncology Trial B: Background and Budget

52           Figure 1.19: Oncology Trial B: Cost Metrics and Staffing

53           Figure 1.20: Oncology Trial B: Duration and Enrollment

54           Oncology Trial B

55           Figure 1.21: Oncology Trial C: Background and Budget

56           Figure 1.22: Oncology Trial C: Staffing and Enrollment

57           Figure 1.23: Oncology Trial C: Duration

58           Oncology Trial B

59           Figure 1.24: Oncology Trial D: Background and Budget

60           Figure 1.25: Oncology Trial D: Cost Metrics and Staffing

61           Figure 1.26: Oncology Trial D: Duration and Enrollment

62           Oncology Trial B

63           Figure 1.27: Oncology Trial E: Background and Budget

64           Figure 1.28: Oncology Trial E: Cost Metrics and Staffing

65           Figure 1.29: Oncology Trial E: Duration

66           Oncology Trial B

67           Figure 1.30: Oncology Trial F: Background and Budget

68           Figure 1.31: Oncology Trial F: Duration and Enrollment

69           Oncology Trial B

70           Figure 1.32: Oncology Trial G: Background and Budget

71           Figure 1.33: Oncology Trial G: Staffing and Enrollment

72           Figure 1.34: Oncology Trial G: Duration

73           Oncology Trial B

74           Figure 1.35: Oncology Trial H: Background and Budget

75           Figure 1.36: Oncology Trial H: Cost Metrics and Staffing

76           Figure 1.37: Oncology Trial H: Duration and Enrollment

77           Oncology Trial B

78           Figure 1.38: Oncology Trial I: Background and Budget

79           Figure 1.39: Oncology Trial I: Cost Metrics and Staffing

80           Figure 1.40: Oncology Trial I: Duration and Enrollment

81           Oncology Trial B

82           Figure 1.41: Oncology Trial J: Background and Budget

83           Figure 1.42: Oncology Trial J: Cost Metrics and Enrollment

84           Figure 1.43: Oncology Trial J: Duration

85           Oncology Trial B

86           Figure 1.44: Oncology Trial K: Background and Budget

87           Figure 1.45: Oncology Trial K: Staffing

88           Figure 1.46: Oncology Trial K: Duration and Enrollment

89           Phase 2 Oncology Trials

89           Figure 2.1: Phase 2 Total Trial Costs, by Trial

90           Figure 2.2: Phase 2 Percentage of Costs Outsourced, by Trial

92           Figure 2.3: Phase 2 Average Planned/Actual Patient Enrollment

92           Phase 2 Cost-Drivers

93           Figure 2.4: Phase 2 Planned and Actual Patient Enrollment, by Trial

94           Figure 2.5: Patient Enrollment Drives Phase 2 Trial Costs

95           Figure 2.6: Phase 2 Cost Per Patient, by Trial

96           Figure 2.7: Phase 2 Actual Trial Duration, by Trial

97           Figure 2.8: Trial Duration and Phase 2 Trial Costs

98           Figure 2.9: Phase 2 Cost Per Patient Per Month, by Trial

99           Phase 2 Staffing

100         Figure 2.10: Average Phase 2 Staffing, by Position

102        Figure 2.11: Phase 2 Number of Patients Per CRA

103        Figure 2.12: Phase 2 Number of Sites, by Trial

104        Figure 2.13: Phase 2 Number of Patients Per Site, by Trial

105        Figure 2.14: Phase 2 Number of Sites Per CRA, by Trial

106        Phase 2 Oncology Trial Case Studies

109        Oncology Trial L

110        Figure 2.15: Oncology Trial L: Background and Budget

111         Figure 2.16: Oncology Trial L: Cost Metrics and Staffing

112        Figure 2.17: Oncology Trial L: Duration and Enrollment

113        Oncology Trial M

115        Figure 2.18: Oncology Trial M: Background and Budget

116         Figure 2.19: Oncology Trial M: Staffing and Enrollment

117        Figure 2.20: Oncology Trial M: Duration

118        Oncology Trial N

119        Figure 2.21: Oncology Trial N: Background and Budget

120        Figure 2.22: Oncology Trial N: Cost Metrics and Enrollment

121        Figure 2.23: Oncology Trial N: Duration

122        Oncology Trial O

124        Figure 2.24: Oncology Trial O: Background and Budget

125         Figure 2.25: Oncology Trial O: Staffing

126        Figure 2.26: Oncology Trial O: Duration and Enrollment

127        Oncology Trial P

129        Figure 2.27: Oncology Trial P: Background and Budget

130         Figure 2.28: Oncology Trial P: Staffing and Enrollment

131        Figure 2.29: Oncology Trial P: Duration

132        Oncology Trial Q

134        Figure 2.30: Oncology Trial Q: Background and Budget

135         Figure 2.31: Oncology Trial Q: Staffing

136         Figure 2.32: Oncology Trial Q: Duration and Enrollment

137         Oncology Trial R

139         Figure 2.33: Oncology Trial R: Background and Budget

140         Figure 2.34: Oncology Trial R: Staffing and Enrollment

141        Figure 2.35: Oncology Trial R: Duration

142        Oncology Trial S

143        Figure 2.36: Oncology Trial S: Background and Budget

144         Figure 2.37: Oncology Trial S: Staffing

145        Figure 2.38: Oncology Trial S: Duration and Enrollment

146        Oncology Trial T

147         Figure 2.39: Oncology Trial T: Background and Budget

148         Figure 2.40: Oncology Trial T: Staffing

149         Figure 2.41: Oncology Trial T: Duration and Enrollment

150         Phase 3 Oncology Trials

151         Figure 3.1: Phase 3 Total Trial Costs, by Trial

152         Figure 3.2: Phase 3 Percentage of Costs Outsourced, by Trial

153         Phase 3 Cost-Drivers

153         Figure 3.3: Phase 3 Average Planned and Actual Patient Enrollment

154         Figure 3.4: Phase 3 Planned and Actual Patient Enrollment, by Trial

155         Figure 3.5: Patient Enrollment Drives Phase 3 Trial Costs

157         Figure 3.6: Phase 3 Cost Per Patient, by Trial

158         Figure 3.7: Phase 3 Actual Duration, by Trial

159         Figure 3.8: Trial Duration and Phase 3 Trial Costs

160         Figure 3.9: Phase 3 Cost Per Patient Per Month, by Trial

161         Phase 3 Staffing

162         Figure 3.10: Average Phase 3 Staffing, by Position

164         Figure 3.11: Number of Patients Per CRA, by Trial

165         Figure 3.12: Phase 3 Number of Sites, by Trial

166         Figure 3.13: Phase 3 Number of Patients Per Site, by Trial

167         Figure 3.14: Phase 3 Number of Sites Per CRA

168         Phase 3 Oncology Trial Case Studies

171         Oncology Trial U

173         Figure 3.15: Oncology Trial U: Background and Budget

174         Figure 3.16: Oncology Trial U: Staffing and Enrollment

175         Figure 3.17: Oncology Trial U: Duration

176         Oncology Trial V

178         Figure 3.18: Oncology Trial V: Background and Budget

179         Figure 3.19: Oncology Trial V: Staffing and Enrollment

180         Figure 3.20: Oncology Trial V: Duration

181         Oncology Trial W

183         Figure 3.21: Oncology Trial W: Background and Budget

184         Figure 3.22: Oncology Trial W: Staffing and Enrollment

185         Figure 3.23: Oncology Trial W: Duration

186         Oncology Trial X

188         Figure 3.24: Oncology Trial X: Background and Budget

189         Figure 3.25: Oncology Trial X: Cost Metrics and Staffing

190         Figure 3.26: Oncology Trial X: Duration and Enrollment

191         Oncology Trial Y

193         Figure 3.27: Oncology Trial Y: Background and Budget

194         Figure 3.28: Oncology Trial Y: Staffing and Enrollment

195         Figure 3.29: Oncology Trial Y: Duration

196         Oncology Trial Z

197         Figure 3.30: Oncology Trial Z: Background and Budget

198         Figure 3.31: Oncology Trial Z: Staffing

199         Figure 3.32: Oncology Trial Z: Duration

200         Oncology Trial AA

201         Figure 3.33: Oncology Trial AA: Background and Budget

202         Figure 3.34: Oncology Trial AA: Staffing

203         Figure 3.35: Oncology Trial AA: Duration and Enrollment

204         Oncology Trial BB

205         Figure 3.36: Oncology Trial BB: Background and Budget

206         Figure 3.37: Oncology Trial BB: Cost Metrics

207         Figure 3.38: Oncology Trial BB: Duration and Enrollment

208         Oncology Trial CC

209         Figure 3.39: Oncology Trial CC: Background and Budget

210         Figure 3.40: Oncology Trial CC: Cost Metrics

211         Figure 3.41: Oncology Trial CC: Duration and Enrollment